42 results on '"Osteitis Deformans therapy"'
Search Results
2. Paget Disease of Bone: What You Should Know.
- Subjects
- Humans, Osteitis Deformans diagnosis, Osteitis Deformans physiopathology, Osteitis Deformans therapy
- Published
- 2020
3. Paget Disease of Bone for Primary Care.
- Author
-
Rianon NJ and des Bordes JK
- Subjects
- Alkaline Phosphatase blood, Arthritis etiology, Bone Neoplasms etiology, Collagen Type I blood, Fractures, Compression etiology, Gait, Hearing Loss etiology, Humans, Nerve Compression Syndromes etiology, Osteitis Deformans complications, Osteosarcoma etiology, Pain drug therapy, Pain etiology, Pain Management, Peptides blood, Practice Guidelines as Topic, Primary Health Care, Radiography, Radionuclide Imaging, Analgesics therapeutic use, Bone Density Conservation Agents therapeutic use, Diphosphonates therapeutic use, Osteitis Deformans diagnosis, Osteitis Deformans therapy
- Abstract
Paget disease of bone is a benign disorder characterized by focal areas of increased bone turnover in one or more skeletal sites. It usually affects older adults, and men are at a higher risk than women. Any bone may be affected, but the disease has a high preference for the pelvis, spine, skull, and long bones. Pain is the most common symptom, and presentation of the disease may depend on which bones are affected, the extent of involvement, and the presence of complications. Paget disease of bone may be asymptomatic, and suspicion arises from incidental findings of elevated serum alkaline phosphatase levels on routine blood work or abnormalities on imaging tests performed for an unrelated cause. Evidence-based guidelines recommend the use of plain radiography and serum alkaline phosphatase testing for initial diagnosis and radionuclide scans for delineation of the extent of disease. Treatment with nitrogen-containing bisphosphonates is recommended in active disease or when risk of complications is possible. Complications of the disease include arthritis, gait changes, hearing loss, nerve compression syndromes, and osteosarcoma. Total serum alkaline phosphatase is the suggested marker for assessing treatment response when high bone turnover occurs, and it should be measured at three to six months to evaluate initial response. Early diagnosis of Paget disease of bone remains key to its management because patients generally have a good prognosis if treatment is initiated before major complications arise. The primary care physician may need to consult with a specialist for confirmation of diagnosis and initiation of treatment.
- Published
- 2020
4. Clinical Guidelines on Paget's Disease of Bone.
- Author
-
Ralston SH, Corral-Gudino L, Cooper C, Francis RM, Fraser WD, Gennari L, Guanabens N, Javaid MK, Layfield R, O'Neill TW, Russell RGG, Stone MD, Simpson K, Wilkinson D, Wills R, Zillikens MC, and Tuck SP
- Subjects
- Biomarkers metabolism, Humans, Osteitis Deformans diagnosis, Osteitis Deformans therapy, Osteitis Deformans pathology, Practice Guidelines as Topic
- Published
- 2019
- Full Text
- View/download PDF
5. Paget disease of bone among hospitalized patients in Poland.
- Author
-
Kanecki K, Nitsch-Osuch A, Goryński P, Bogdan M, Tarka P, and Tyszko PZ
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Hospitalization, Humans, Infant, Male, Middle Aged, Osteitis Deformans therapy, Patients statistics & numerical data, Poland epidemiology, Young Adult, Osteitis Deformans epidemiology
- Abstract
Introduction: Paget's disease (PDB) is a focal disorder of bone remodeling that occurs commonly in older people with decreasing prevalence reported in European countries. This disease is most often asymptomatic, but it can cause a variety of medical complications resulting in considerable morbidity and reduced quality of life. There is little information regarding the epidemiology of PDB in Poland. To the best of the authors' knowledge, this is the first large epidemiological analysis of this disease in Poland., Objective: The aim of this study was to analyze factors that may be related to the PDB epidemiology among hospitalized patients in Poland., Material and Methods: The analysis was conducted on the basis of population-based administrative data, taken from a Polish hospital morbidity study carried out by the National Institute of Public Health between January 2008 - December 2014., Results: Analyzed data covered 662 hospitalization records. The final study sample comprised 94 (41.8%) male and 131 (58.2%) female patients with first-time hospitalizations for PDB, with a significant predominance of females (P<0.02), and the predominance of patients living in urban (73%) than in rural areas (27%), P<0.001. The average age of the sample was 56.8 years (CI: 54.3-59.3; SD 18.8; range 1-93 years). The number of PDB cases hospitalized in Poland significantly decreased during the analyzed period of time., Conclusions: PDB is a rare disease with decreasing trends observed among hospitalized patients in Poland. The study results may suggest the existence of environmental risk factors for the development of PDB.
- Published
- 2018
- Full Text
- View/download PDF
6. Long-Term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISM-EZ Study.
- Author
-
Tan A, Goodman K, Walker A, Hudson J, MacLennan GS, Selby PL, Fraser WD, and Ralston SH
- Subjects
- Aged, Alkaline Phosphatase blood, Analgesics therapeutic use, Diphosphonates therapeutic use, Female, Fractures, Bone complications, Humans, Male, Orthopedic Procedures, Osteitis Deformans blood, Osteitis Deformans drug therapy, Pain drug therapy, Quality of Life, Osteitis Deformans therapy
- Abstract
It has been suggested that normalization of bone turnover may improve clinical outcome in Paget's disease of bone (PDB) by preventing complications such as fractures and the development of osteoarthritis. Here we investigated the long-term effects of a treatment strategy that aimed to normalize bone turnover in PDB with that of symptomatic treatment. The study group comprised 502 subjects who were enrolled into a 3-year extension of the Paget's Disease: Randomized Trial of Intensive versus Symptomatic Management (PRISM) study. Intensive bisphosphonate therapy was continued in 270 of these subjects with the aim of normalizing bone turnover using zoledronic acid as the treatment of first choice. Symptomatic treatment continued in 232 subjects in whom bisphosphonates were only given for the treatment of bone pain. The primary outcome was fracture and secondary outcomes were orthopedic procedures, quality of life, and bone pain, adjusted for baseline characteristics. Serum total alkaline phosphatase (ALP) concentrations were significantly lower in the intensive group on entry to the study and the differences between groups increased as the study progressed. There were no clinically important differences in quality of life measures or bone pain between the treatment groups. Intensive treatment was associated with a nonsignificant increase in fracture risk (hazard ratio = 1.90; 95% CI, 0.91 to 3.98; p = 0.087), orthopedic procedures (1.81; 95% CI, 0.71 to 4.61; p = 0.214), and serious adverse events (relative risk 1.28; 95% CI, 0.96 to 1.42). We conclude that long-term intensive bisphosphonate therapy confers no clinical benefit over symptomatic therapy and is associated with a nonsignificant increase in the risk of fractures, orthopedic events, and serious adverse events. The results of this study suggest that in patients with established PDB, bisphosphonate therapy should focus on control of symptoms rather than suppression of bone turnover. © 2016 American Society for Bone and Mineral Research., (© 2016 American Society for Bone and Mineral Research.)
- Published
- 2017
- Full Text
- View/download PDF
7. Clinical characteristics and prognoses of six patients with multicentric giant cell tumor of the bone.
- Author
-
Liu C, Tang Y, Li M, Jiao Q, Zhang H, Yang Q, and Yao W
- Subjects
- Adolescent, Adult, Biopsy, Bone Density Conservation Agents therapeutic use, Denosumab therapeutic use, Female, Humans, Magnetic Resonance Imaging, Male, Neoplasm Recurrence, Local, Osteotomy, Positron Emission Tomography Computed Tomography, Retrospective Studies, Treatment Outcome, Young Adult, Bone Neoplasms diagnostic imaging, Bone Neoplasms pathology, Bone Neoplasms therapy, Giant Cell Tumor of Bone diagnostic imaging, Giant Cell Tumor of Bone pathology, Giant Cell Tumor of Bone therapy, Osteitis Deformans diagnostic imaging, Osteitis Deformans pathology, Osteitis Deformans therapy, Osteosarcoma diagnostic imaging, Osteosarcoma pathology, Osteosarcoma therapy
- Abstract
Multicentric giant cell tumor of the bone (MGCT) is a rare entity whose radiographic, pathological and biological features remain confusing. We retrospectively reviewed six patients (1 male, 5 female; average age, 22.33 years) treated for confirmed MGCT between 2001 and 2015. The patients' clinical information, images from radiographs (n = 14), CT (n = 13), MRI (n = 8), bone scintigraphy (n = 1) and PET-CT (n = 2), as well as histologic features, treatment and prognosis were analyzed. A total of 17 lesions were detected: 4 around the knee joint, 3 in the greater trochanter and head of the femur, 5 in the small bones of the feet, and 2 in flat bones. All these lesions occurred in an ipsilateral extremity. One patient had Paget's disease. On radiographs and CT, 12 lesions exhibited sclerotic margins or patchy sclerosis, 8 showed cortical discontinuity, and 5 showed soft tissue masses. On histopathology, 8 lesions showed signs of sarcomatous transformation and one had transformed into osteosarcoma. Ten lesions in 4 patients were initially treated with surgery, and 3 showed local recurrence. Seven lesions in 3 patients were treated with denosumab. All the patients are currently stable without metastasis. These results suggest MGCT tends to occur in uncommon sites with sclerosis. Because these lesions can be aggressive, patients should be carefully monitored for the recurrence or formation of other lesions, especially in an ipsilateral extremity.
- Published
- 2016
- Full Text
- View/download PDF
8. Letter to the Editor: The Endocrine Society Clinical Practice Guidelines on Paget's Disease: Many Recommendations Are Not Evidence Based.
- Author
-
Ralston SH, Corral-Gudino L, Fraser WD, Gennari L, Guañabens N, and Selby PL
- Subjects
- Humans, Osteitis Deformans therapy
- Published
- 2015
- Full Text
- View/download PDF
9. Response to letter by Ralston et al.
- Author
-
Singer FR, Bone HG 3rd, Hosking DJ, Lyles KW, Reid IR, and Siris ES
- Subjects
- Humans, Osteitis Deformans therapy
- Published
- 2015
- Full Text
- View/download PDF
10. Response to letter.
- Author
-
Singer FR, Bone HG 3rd, Hoskings DJ, Lyles KW, Reid IR, and Siris ES
- Subjects
- Humans, Osteitis Deformans therapy
- Published
- 2015
- Full Text
- View/download PDF
11. Letter to the editor: Comment on Pagets disease clinical practice guideline by Singer et al.
- Author
-
Gutteridge DH
- Subjects
- Humans, Osteitis Deformans therapy
- Published
- 2015
- Full Text
- View/download PDF
12. Letter to the editor: Treatment of Paget's disease in patients with renal impairment.
- Author
-
Asik M, Kadioglu GK, Eroglu M, Sen H, Erbag G, and Ukinc K
- Subjects
- Humans, Osteitis Deformans therapy
- Published
- 2015
- Full Text
- View/download PDF
13. Response to the letter by Asik M., et al.
- Author
-
Singer FR, Bone HG 3rd, Hosking DJ, Lyles KW, Murad MH, Reid IR, and Siris ES
- Subjects
- Humans, Osteitis Deformans therapy
- Published
- 2015
- Full Text
- View/download PDF
14. Paget's disease of bone: an endocrine society clinical practice guideline.
- Author
-
Singer FR, Bone HG 3rd, Hosking DJ, Lyles KW, Murad MH, Reid IR, and Siris ES
- Subjects
- Biomarkers analysis, Consensus, Evidence-Based Medicine, Humans, Osteitis Deformans complications, Osteitis Deformans diagnosis, Reproducibility of Results, Osteitis Deformans therapy
- Abstract
Objective: The aim of this guideline was to formulate practice guidelines for the diagnosis and treatment of Paget's disease of the bone., Participants: The guideline was developed by an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer., Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence., Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence., Conclusions: We recommend that plain radiographs be obtained of the pertinent regions of the skeleton in patients with suspected Paget's disease. If the diagnosis is confirmed, we suggest that a radionucleotide bone scan be done to determine the extent of the disease. After diagnosis of Paget's disease, we recommend measurement of serum total alkaline phosphatase or, when warranted, a more specific marker of bone formation or bone resorption to assess the response to treatment or evolution of the disease in untreated patients. We suggest treatment with a bisphosphonate for most patients with active Paget's disease who are at risk for future complications. We suggest a single 5-mg dose of iv zoledronate as the treatment of choice in patients who have no contraindication. In patients with monostotic disease who have a normal serum total alkaline phosphatase, we suggest that a specific marker of bone formation and bone resorption be measured, although these may still be normal. Serial radionuclide bone scans may determine the response to treatment if the markers are normal. We suggest that bisphosphonate treatment may be effective in preventing or slowing the progress of hearing loss and osteoarthritis in joints adjacent to Paget's disease and may reverse paraplegia associated with spinal Paget's disease. We suggest treatment with a bisphosphonate before surgery on pagetic bone.
- Published
- 2014
- Full Text
- View/download PDF
15. Paget's disease of bone.
- Author
-
Tan A and Ralston SH
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Bone Density Conservation Agents therapeutic use, Bone Remodeling physiology, Environmental Exposure adverse effects, Forecasting, Fractures, Spontaneous etiology, Genetic Predisposition to Disease genetics, Humans, Musculoskeletal Pain etiology, Mutation genetics, Osteoprotegerin genetics, Practice Guidelines as Topic, Receptor Activator of Nuclear Factor-kappa B genetics, Sequestosome-1 Protein, Osteitis Deformans diagnosis, Osteitis Deformans etiology, Osteitis Deformans therapy
- Abstract
Paget's disease of bone is a common disorder characterized by increased but disorganized bone remodelling. Some patients are asymptomatic but others present with bone pain or other complications such as fracture and deformity. Major advances have been made in understanding the pathophysiology of Paget's disease in recent years and highly effective agents are now available with which to suppress the abnormal bone turnover that causes the disease. Here we review recent advances in the epidemiology, pathogenesis, clinical features and management of Paget's disease. We also reflect upon the future challenges that remain to be overcome to explain the unusual distribution of the disease and to favourably alter the natural history and prevent the development of complications., (© The Author 2014. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2014
- Full Text
- View/download PDF
16. Paget's disease.
- Author
-
Bertoldi I, Cantarini L, Filippou G, and Frediani B
- Subjects
- Humans, Osteitis Deformans complications, Osteitis Deformans diagnosis, Osteitis Deformans epidemiology, Osteitis Deformans etiology, Osteitis Deformans therapy
- Abstract
Paget's disease of bone is the most common metabolic bone disease after osteoporosis and affects 2-4% of adults over 55 years of age. Its etiology is only partly understood and includes both genetic and environmental factors. The disease may be asymptomatic and can be uncovered incidentally on x-ray or in biochemical tests performed for another condition. It can also manifest itself with bone pain, deformity, fracture or other complications. Paget's disease is diagnosed by x-rays and in general has very typical radiological features, but occasionally the clinical picture may be unusual and a differential diagnosis of sclerotic or lytic metastases needs to be considered. Plasma total alkaline phosphatase activity is the most clinically useful indicator of disease activity. It is elevated in most untreated patients, but may be within the normal range in patients with monostotic or limited disease. Bisphosphonate therapy is indicated for patients with symptoms and should also be considered in patients with disease sites that suggest a risk of complications, such as long bones, vertebrae or base of the skull. Orthopedic surgery in Paget's disease patients includes almost exclusively the correction of fractures and arthroplasty.
- Published
- 2014
- Full Text
- View/download PDF
17. New insights into the role of sequestosome 1/p62 mutant proteins in the pathogenesis of Paget's disease of bone.
- Author
-
Rea SL, Walsh JP, Layfield R, Ratajczak T, and Xu J
- Subjects
- Adaptor Proteins, Signal Transducing metabolism, Animals, Apoptosis, Autophagy, Cell Survival, Humans, Osteitis Deformans diagnosis, Osteitis Deformans metabolism, Osteitis Deformans therapy, Oxidative Stress, Proteasome Endopeptidase Complex metabolism, RANK Ligand metabolism, Sequestosome-1 Protein, Signal Transduction, TNF Receptor-Associated Factor 6 metabolism, Ubiquitinated Proteins metabolism, Adaptor Proteins, Signal Transducing genetics, Models, Biological, Mutation, Osteitis Deformans genetics, Osteoclasts metabolism
- Abstract
Paget's disease of bone (PDB) is characterized by focal areas of aberrant and excessive bone turnover, specifically increased bone resorption and disorganized bone formation. Germline mutations in the sequestosome 1/p62 (SQSTM1/p62) gene are common in PDB patients, with most mutations affecting the ubiquitin-associated domain of the protein. In vitro, osteoclast precursor cells expressing PDB-mutant SQSTM1/p62 protein are associated with increases in nuclear factor κB activation, osteoclast differentiation, and bone resorption. Although the precise mechanisms by which SQSTM1/p62 mutations contribute to disease pathogenesis and progression are not well defined, it is apparent that as well as affecting nuclear factor κB signaling, SQSTM1/p62 is a master regulator of ubiquitinated protein turnover via autophagy and the ubiquitin-proteasome system. Additional roles for SQSTM1/p62 in the oxidative stress-induced Keap1/Nrf2 pathway and in caspase-mediated apoptosis that were recently reported are potentially relevant to the pathogenesis of PDB. Thus, SQSTM1/p62 may serve as a molecular link or switch between autophagy, apoptosis, and cell survival signaling. The purpose of this review is to outline recent advances in understanding of the multiple pathophysiological roles of SQSTM1/p62 protein, with particular emphasis on their relationship to PDB, including challenges associated with translating SQSTM1/p62 research into clinical diagnosis and treatment.
- Published
- 2013
- Full Text
- View/download PDF
18. Osteosarcoma arising on a background of Paget's disease report of an unusual case.
- Author
-
Qureshi A, Zahid KF, Ibrahim SI, and Burney I
- Subjects
- Aged, Bone Neoplasms therapy, Hip Joint pathology, Hip Joint surgery, Humans, Lymphoma, Follicular complications, Male, Osteitis Deformans therapy, Osteosarcoma therapy, Bone Neoplasms complications, Bone Neoplasms diagnosis, Osteitis Deformans complications, Osteitis Deformans diagnosis, Osteosarcoma complications, Osteosarcoma diagnosis
- Abstract
One of the serious complications of Paget's disease (PD) is a significant increase in the risk of developing osteosarcoma. Approximately 1% of the patients with PD develop osteosarcoma. This contributes significantly to the mortality and morbidity of the patients with PD. We present the case of an elderly person, who developed osteosarcoma 1 year after being diagnosed to have PD. The patient had been diagnosed to have lymphoma 8 years prior to the diagnosis of PD. The association between PD and follicular lymphoma is discussed.
- Published
- 2013
- Full Text
- View/download PDF
19. Treatment of Paget's disease of bone.
- Author
-
Lojo Oliveira L and Torrijos Eslava A
- Subjects
- Alkaline Phosphatase blood, Biomarkers, Calcium therapeutic use, Collagen Type I blood, Diphosphonates therapeutic use, Disease Management, Elective Surgical Procedures, Fractures, Spontaneous prevention & control, Humans, Hypercalcemia etiology, Nerve Compression Syndromes etiology, Nerve Compression Syndromes prevention & control, Osteitis Deformans complications, Osteitis Deformans pathology, Osteitis Deformans surgery, Recurrence, Vitamin D therapeutic use, Osteitis Deformans therapy
- Abstract
Paget's disease of bone is the paradigm of bone focal distortion with accelerated bone turnover. Over the years, a number of different drugs have been used to control its activity but, since biphosphonates were introduced for the treatment of the disease, they have become the preferred treatment. This review will update the therapeutic indications, available drugs and therapeutic response monitoring., (Copyright © 2011 Elsevier España, S.L. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
20. A woman with raised alkaline phosphatase and forearm deformity.
- Author
-
Lam JK, Lam KS, Kung AW, Tan KC, Chow WS, and Tso AW
- Subjects
- Aged, Diagnosis, Differential, Female, Humans, Osteitis Deformans blood, Osteitis Deformans diagnosis, Osteitis Deformans pathology, Osteitis Deformans therapy, Alkaline Phosphatase blood, Forearm abnormalities
- Published
- 2011
- Full Text
- View/download PDF
21. Emerging strategies and therapies for treatment of Paget's disease of bone.
- Author
-
Michou L and Brown JP
- Subjects
- Animals, Bone Resorption drug therapy, Clinical Trials as Topic, Diphosphonates pharmacology, Humans, Osteitis Deformans diagnosis, Osteitis Deformans etiology, Osteitis Deformans physiopathology, Diphosphonates therapeutic use, Osteitis Deformans therapy
- Abstract
Paget's disease of bone (PDB) is a progressive monostotic or polyostotic metabolic bone disease characterized by focal abnormal bone remodeling, with increased bone resorption and excessive, disorganized, new bone formation. PDB rarely occurs before middle age, and it is the second most frequent metabolic bone disorder after osteoporosis, affecting up to 3% of adults over 55 years of age. One of the most striking and intriguing clinical features is the focal nature of the disorder, in that once the disease is established within a bone, there is only local spread within that bone and no systemic dissemination. Despite many years of intense research, the etiology of PDB has still to be conclusively determined. Based on a detailed review of genetic and viral factors incriminated in PDB, we propose a unifying hypothesis from which we can suggest emerging strategies and therapies. PDB results in weakened bone strength and abnormal bone architecture, leading to pain, deformity or, depending on the bone involved, fracture in the affected bone. The diagnostic assessment includes serum total alkaline phosphatase, total body bone scintigraphy, skull and enlarged view pelvis x-rays, and if needed, additional x-rays. The ideal therapeutic option would eliminate bone pain, normalize serum total alkaline phosphatase with prolonged remission, heal radiographic osteolytic lesions, restore normal lamellar bone, and prevent recurrence and complications. With the development of increasingly potent bisphosphonates, culminating in the introduction of a single intravenous infusion of zoledronic acid 5 mg, these goals of treatment are close to being achieved, together with long-term remission in almost all patients. Based on the recent pathophysiological findings, emerging strategies and therapies are reviewed: ie, pulse treatment with zoledronic acid; denosumab, a fully human monoclonal antibody directed against RANK ligand; tocilizumab, an interleukin-6 receptor inhibitor; odanacatib, a cathepsin K inhibitor; and proteasome and Dickkopf-1 inhibitors.
- Published
- 2011
- Full Text
- View/download PDF
22. Juvenile Paget's disease.
- Author
-
Indumathi CK, Dinakar C, and Roshan R
- Subjects
- Adolescent, Humans, Male, Osteitis Deformans complications, Osteitis Deformans therapy, Osteitis Deformans diagnosis
- Abstract
Juvenile Pagets disease (JPD), a rare genetic disorder characterized by markedly accelerated bone turnover, presents in early childhood. We report a child with typical features of JPD who remained undiagnosed till 15 years of age. Rarity of this disease in Indian literature and need for early diagnosis to prevent progression of disease prompted us to report this case.
- Published
- 2009
23. Silent swelling of the tibia in a 43-year-old man.
- Author
-
Ocguder A, Tecimel O, Firat A, and Bozkurt M
- Subjects
- Adult, Diagnosis, Differential, Humans, Magnetic Resonance Imaging, Male, Osteitis Deformans complications, Osteitis Deformans diagnostic imaging, Osteitis Deformans therapy, Pain etiology, Pain pathology, Tibia diagnostic imaging, Tomography, X-Ray Computed, Osteitis Deformans pathology, Tibia pathology
- Published
- 2008
- Full Text
- View/download PDF
24. Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases.
- Author
-
Deyrup AT, Montag AG, Inwards CY, Xu Z, Swee RG, and Krishnan Unni K
- Subjects
- Adult, Aged, Aged, 80 and over, Bone Neoplasms mortality, Bone Neoplasms therapy, Combined Modality Therapy, Comorbidity, Female, Humans, Male, Middle Aged, Osteitis Deformans mortality, Osteitis Deformans therapy, Osteosarcoma mortality, Osteosarcoma therapy, Prognosis, Retrospective Studies, Survival Rate, Bone Neoplasms pathology, Osteitis Deformans pathology, Osteosarcoma pathology
- Abstract
Context: Sarcomatous transformation is a rare complication of Paget disease of bone. Prognosis in patients with other types of sarcomas arising in bone has improved in the last several decades because of therapeutic advances. However, because of the rarity of Paget sarcoma, outcome studies in these patients are limited., Objective: To determine whether prognosis for Paget sarcoma has improved., Design: Seventy cases of sarcomas arising in the setting of Paget disease were collected, and the histologic and clinical findings were reviewed. Clinical follow-up was obtained in 67 cases., Results: Sarcoma arising in Paget disease tended to arise in older men (46 men, 24 women; age range, 31-88 years; mean age, 66 years) and predominated in the axial skeleton (n = 37), especially in the pelvis. Thirty-three patients had a clinical history of Paget disease ranging in duration from 16 months to 30 years (mean, 15 years). No significant difference in incidence between monostotic (n = 33) and polyostotic (n = 36) disease was noted. Most tumors were osteosarcomas (88%). All tumors were high grade. Follow-up information was obtained in 67 of 70 cases (range of follow-up, 1-252 months). Survival ranged from 1 month to 20 years, with a 5-year survival rate of 10%., Conclusions: Prognosis remains poor in patients with Paget sarcoma. There is no significant correlation between the number of bones involved with Paget disease or the duration of disease and development of Paget sarcoma. Poor prognosis in Paget sarcoma is unrelated to site or stage at presentation.
- Published
- 2007
- Full Text
- View/download PDF
25. [Italian guidelines for the diagnosis and treatment of Paget's disease of bone].
- Author
-
Adami S, Bartolozzi P, Brandi ML, Falchetti A, Filipponi P, Gonnelli S, Bianchi G, Isaia GC, and Nuti R
- Subjects
- Humans, Osteitis Deformans diagnosis, Osteitis Deformans therapy
- Abstract
Paget's disease of bone is a chronic focal abnormality of bone turnover that remains totally asymptomatic over a very long period of time but that eventually ensue in bone pain and skeletal deformities. Although, in the last decade new insights have been obtained on its etiology, this remains largely obscure. Effective medical treatment (based on the use of bisphosphonates) has become available and the diagnostic procedures are now well defined. However, there remains considerable controversy regarding the hierarchy of diagnostic procedures and the medical treatment threshold. In the last few years different institution have published national guidelines, reflecting local national health systems and the available medical treatment. In this review, a working group derived from members of the SIOMMMS has examined the information available regarding the diagnosis and treatment of Paget's disease in order to develop guidelines to assist in the management of this condition. The first draft was then extensively reviewed by experts derived from the most representative scientific societies of rheumatology, internal medicine, and orthopaedic surgery. The document provides the most updated recommendations based primarily on the "evidence-based- medicine" but also on the Italian regulation for the diagnostic procedures and on the available medical treatments.
- Published
- 2007
26. Paget disease of bone. Diagnosis and indications for treatment.
- Author
-
Kotowicz MA
- Subjects
- Adult, Diphosphonates therapeutic use, Humans, Male, Osteitis Deformans complications, Osteitis Deformans therapy, Osteitis Deformans diagnosis
- Abstract
Background: Paget disease was first described in 1877 by Sir James Paget. It is a focal disorder of bone remodelling, involving increased bone resorption and formation. The aetiology is uncertain but both environmental and genetic factors are thought to be involved in pathogenesis., Objective: This article outlines the clinical presentation, diagnosis and treatment of Paget disease., Discussion: Paget disease is associated with musculoskeletal pain, significant disability and impaired quality of life. Complications include pathological fracture, arthritis in adjacent joints, hearing loss, other neurological complications, heart failure and, rarely, osteosarcoma. Recent clinical trial data has demonstrated histological and radiological improvements in bone of patients treated with bisphosphonates. There is little data evaluating the long term effect of therapy on the risk of complications, however, restoration of normal bony architecture offers the prospect that complications related to deformity and increased bone fragility might be reduced by effective therapy.
- Published
- 2004
27. UK guidelines on management of Paget's disease of bone.
- Author
-
Scarsbrook A, Brown M, and Wilson D
- Subjects
- Cost-Benefit Analysis, Health Priorities, Humans, Middle Aged, Osteitis Deformans therapy, Practice Guidelines as Topic, Radionuclide Imaging, Bone and Bones diagnostic imaging, Osteitis Deformans diagnostic imaging
- Published
- 2004
- Full Text
- View/download PDF
28. Patient education. Paget disease of bone.
- Author
-
Kotowicz MA
- Subjects
- Humans, Osteitis Deformans diagnosis, Osteitis Deformans therapy
- Published
- 2004
29. Principles of management of osteometabolic disorders affecting the aging spine.
- Author
-
Hadjipavlou AG, Katonis PG, Tzermiadianos MN, Tsoukas GM, and Sapkas G
- Subjects
- Aged, Humans, Orthopedic Procedures methods, Osteitis Deformans pathology, Osteitis Deformans therapy, Spinal Diseases therapy, Spinal Stenosis etiology, Spinal Stenosis pathology, Spinal Stenosis therapy, Aging pathology, Osteitis Deformans complications, Osteoporosis complications, Spinal Diseases etiology
- Abstract
Osteoporosis is the most common contributing factor of spinal fractures, which characteristically are not generally known to produce spinal cord compression symptoms. Recently, an increasing number of medical reports have implicated osteoporotic fractures as a cause of serious neurological deficit and painful disabling spinal deformities. This has been corroborated by the present authors as well. These complications are only amenable to surgical management, requiring instrumentation. Instrumenting an osteoporotic spine, although a challenging task, can be accomplished if certain guidelines for surgical techniques are respected. Neurological deficits respond equally well to an anterior or posterior decompression, provided this is coupled with multisegmental fixation of the construct. With the steady increase in the elderly population, it is anticipated that the spine surgeon will face serious complications of osteoporotic spines more frequently. With regard to surgery, however, excellent correction of deformities can be achieved, by combining anterior and posterior approaches. Paget's disease of bone (PD) is a non-hormonal osteometabolic disorder and the spine is the second most commonly affected site. About one-third of patients with spinal involvement exhibit symptoms of clinical stenosis. In only 12-24% of patients with PD of the spine is back pain attributed solely to PD, while in the majority of patients, back pain is either arthritic in nature or a combination of a pagetic process and coexisting arthritis. In this context, one must be certain before attributing low back pain to PD exclusively, and antipagetic medical treatment alone may be ineffective. Neural element dysfunction may be attributed to compressive myelopathy by pagetic bone overgrowth, pagetic intraspinal soft tissue overgrowth, ossification of epidural fat, platybasia, spontaneous bleeding, sarcomatous degeneration and vertebral fracture or subluxation. Neural dysfunction can also result from spinal ischemia when blood is diverted by the so-called "arterial steal syndrome". Because the effectiveness of pharmacologic treatment for pagetic spinal stenosis has been clearly demonstrated, surgical decompression should only be instituted after failure of antipagetic medical treatment. Surgery is indicated as a primary treatment when neural compression is secondary to pathologic fractures, dislocations, spontaneous epidural hematoma, syringomyelia, platybasia, or sarcomatous transformation. Five classes of drugs are available for the treatment of PD. Bisphosphonates are the most popular antipagetic drug and several forms have been investigated.
- Published
- 2003
- Full Text
- View/download PDF
30. Diagnosis and treatment of Paget's disease of bone.
- Author
-
Schneider D, Hofmann MT, and Peterson JA
- Subjects
- Calcitonin therapeutic use, Humans, Diphosphonates therapeutic use, Osteitis Deformans diagnosis, Osteitis Deformans etiology, Osteitis Deformans therapy
- Abstract
Paget's disease of bone (also known as osteitis deformans) is a nonmalignant disease involving accelerated bone resorption followed by deposition of dense, chaotic, and ineffectively mineralized bone matrix. The origin of the disease is unknown, and it is frequently asymptomatic; however, the patient may present with symptoms depending on the bones involved. The most common symptom is pain in the affected bone; neurologic, hearing, vision, cardiac, and oncologic complications are possible. Diagnosis is primarily made by radiographs. Bisphosphonates are the most common treatment.
- Published
- 2002
31. Paget's disease of the spine and its management.
- Author
-
Hadjipavlou AG, Gaitanis LN, Katonis PG, and Lander P
- Subjects
- Humans, Osteitis Deformans etiology, Osteitis Deformans genetics, Osteitis Deformans pathology, Prevalence, Spinal Diseases etiology, Spinal Diseases genetics, Spinal Diseases pathology, Osteitis Deformans therapy, Spinal Diseases therapy
- Abstract
A review of the literature was conducted to study the pathomechanics by which Paget's Disease of bone (PD) alters the spinal structures that result in distinct spinal pathologic entities such as pagetic spinal arthritis, spinal stenosis, and other pathologies, and to assess the best treatment options and available drugs. The spine is the second most commonly affected site with PD. About one-third of patients with spinal involvement exhibit symptoms of clinical stenosis. In only 12-24% of patients with PD of the spine is back pain attributed solely to PD, while in the majority of patients back pain is either arthritic in nature or a combination of a pagetic process and coexisting arthritis. Neural element dysfunction may be attributed to compressive myelopathy by pagetic bone overgrowth, pagetic intraspinal soft tissue overgrowth, ossification of epidural fat, platybasia, spontaneous bleeding, sarcomatous degeneration and vertebral fracture or subluxation. Neural dysfunction can also result from spinal ischemia, when blood is diverted by the so-called "arterial steal syndrome". Because the effectiveness of pharmacologic treatment for pagetic spinal stenosis has been clearly demonstrated, surgical decompression should only be instituted after failure of antipagetic medical treatment. Surgery is indicated as a primary treatment when neural compression is secondary to pathologic fractures, dislocations, spontaneous epidural hematoma, syringomyelia, platybasia, or sarcomatous transformation. Since, in the majority of cases with pagetic spinal involvement, there are also coexisting osteoarthritic changes, antipagetic medical treatment alone may be disappointing. Therefore, one must be careful before attributing low back pain to PD alone. Five classes of drugs are available for the treatment of PD: bisphosphonates, calcitonins, mithramycin (plicamycin), gallium nitrate, and ipriflavone. Bisphosphonates are the most popular, and several forms have been investigated, but only the following forms have been approved for clinical use: disodium etidronate, clodronate, aledronate, risedronate, neridronate, pamidronate, tiludronate, ibadronate, aminohydroxylbutylidene bisphosphonate, olpadronate, and zoledronate. Several of these forms are still under investigation.
- Published
- 2001
- Full Text
- View/download PDF
32. A clinical approach to diagnosis and management of Paget's disease of bone.
- Author
-
Lyles KW, Siris ES, Singer FR, and Meunier PJ
- Subjects
- Analgesics therapeutic use, Humans, Osteitis Deformans physiopathology, Patient Care Planning, Osteitis Deformans diagnosis, Osteitis Deformans therapy
- Published
- 2001
- Full Text
- View/download PDF
33. Paget's disease: treatment results and expectations with present therapies.
- Author
-
Meunier PJ
- Subjects
- Humans, Osteitis Deformans therapy
- Published
- 1999
- Full Text
- View/download PDF
34. Goals of treatment for Paget's disease of bone.
- Author
-
Siris ES
- Subjects
- Humans, Osteitis Deformans therapy
- Abstract
The goals of treatment of Paget's disease must be readdressed in the context of the availability of potent bisphosphonate compounds, including pamidronate and, more recently, alendronate and risedronate. These agents differ from the traditional mainstays of therapy, salmon calcitonin and etidronate, in several respects. First, they achieve a reduction in the elevated indices of pagetic bone turnover of about 80%, in contrast with the 50% reduction seen with the older agents. Second, a majority of patients (in the range of 50-75%, depending on the series) achieve biochemical remission, and the duration of remission may exceed 1 year or more after a single course of therapy. Third, with the newer bisphosphonates the quality of newly forming bone after successful treatment is lamellar in appearance (as was the case with etidronate) but there is no clinically significant mineralization abnormality associated with these more recent agents. With prior therapies, the primary goal of treatment was to relieve symptoms. In the absence of complete suppression of abnormal turnover, disease progression was not completely halted in many patients, increasing the risk of long-term complications. The characteristics of the newer agents, however, suggest that in those patients who achieve remission there is a possibility, albeit not yet proven, of arresting progression and reducing the risk of later complications. Many patients have no symptoms at presentation but have active disease at locations where progression could cause bone enlargement and deformity over time. These patients may be considered to be at increased risk of future complications if untreated. Thus, it is recommended that such individuals receive therapy with a potent bisphosphonate with the goal of attaining normal (or near normal) biochemical indices after initial treatment and/or retreatment. Patients should be followed with measurement of serum alkaline phosphatase every 4-6 months after a course of therapy, and retreatment is suggested when indices rise above the upper limit of normal or by 25% above the previous nadir. The uncommon possibility of secondary resistance to a given agent after more than one treatment course should be assessed in all patients.
- Published
- 1999
- Full Text
- View/download PDF
35. Paget's disease of bone.
- Author
-
Ooi CG and Fraser WD
- Subjects
- Humans, Osteoclasts virology, Prevalence, Osteitis Deformans diagnosis, Osteitis Deformans epidemiology, Osteitis Deformans etiology, Osteitis Deformans therapy
- Abstract
Paget's disease of bone is a relatively common condition in the UK affecting up to 5% of the population over the age of 55 years with particularly high prevalence in the North West of England. The majority of those affected are asymptomatic. Its precise cause remains unknown, and until recently, choice of treatment of this sometimes painful and debilitating disease has been limited. In this article, we review various aspects of this disease, concentrating particularly on recent advances in our understanding of its aetiology and its treatment.
- Published
- 1997
- Full Text
- View/download PDF
36. Paget's disease of bone: diagnosis and management.
- Author
-
Hosking D, Meunier PJ, Ringe JD, Reginster JY, and Gennari C
- Subjects
- Humans, Pain etiology, Osteitis Deformans diagnosis, Osteitis Deformans therapy
- Published
- 1996
- Full Text
- View/download PDF
37. Paget's disease of bone.
- Author
-
Strewler GJ
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Osteitis Deformans complications, Osteitis Deformans therapy, Osteitis Deformans diagnosis
- Abstract
These discussions are selected from the weekly staff conferences in the Department of Medicine, University of California, San Francisco. Taken from transcriptions, they are prepared by Drs Homer A. Boushey, Associate Professor of Medicine, and David G. Warnock, Associate Professor of Medicine, under the direction of Dr Lloyd H. Smith, Jr, Professor of Medicine and Chairman of the Department of Medicine. Requests for reprints should be sent to the Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco, CA 94143.
- Published
- 1984
38. Paget's disease of bone.
- Author
-
Siris ES, Jacobs TP, and Canfield RE
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Osteitis Deformans diagnosis, Osteitis Deformans physiopathology, Osteitis Deformans therapy
- Published
- 1980
39. Bone disease in the elderly.
- Author
-
Smith R
- Subjects
- Aged, Female, Humans, Vitamin D therapeutic use, Osteitis Deformans therapy, Osteomalacia diagnosis, Osteomalacia therapy, Osteoporosis therapy
- Published
- 1976
40. Skeletal disease in the elderly.
- Author
-
Leeming JT
- Subjects
- Aging, Bone Neoplasms epidemiology, Bone Neoplasms prevention & control, Bone Neoplasms therapy, Humans, Neoplasm Metastasis, Osteitis Deformans epidemiology, Osteitis Deformans prevention & control, Osteitis Deformans therapy, Osteomalacia epidemiology, Osteomalacia prevention & control, Osteomalacia therapy, Osteoporosis epidemiology, Osteoporosis prevention & control, Osteoporosis therapy, Aged, Bone Diseases
- Published
- 1973
- Full Text
- View/download PDF
41. The relief of pain in Paget's disease (osteitis deformans).
- Author
-
MAUDSLEY RH
- Subjects
- Humans, Adenocarcinoma, Osteitis Deformans therapy, Pain
- Published
- 1957
42. Paget's disease; changes occurring following treatment with newer hormonal agents.
- Author
-
KOLB FO
- Subjects
- Female, Humans, Adrenocorticotropic Hormone therapy, Bone and Bones, Calcium, Dietary, Cortisone therapy, Fractures, Bone, Osteitis Deformans therapy, Osteoporosis, Osteoporosis, Postmenopausal, Vitamin D
- Abstract
From experience in six cases the anabolic steroid hormones, especially long-acting testosterone and estrogen preparations, are the treatment of choice in Paget's disease, as in postmenopausal osteoporosis. Details of the management of three patients over a period of four years are presented. Roughly 4 per cent of the population, mostly persons over 40, show some evidence of Paget's disease. Only a small number of them, however, have severe manifestations requiring treatment, such as pain, howing or fracture of the bones, pressure on nerves or heart failure. In rare cases malignant changes occur in the involved bone. Since the cause of Paget's disease is not known, treatment in the past has been largely empirical. Reifenstein and Albright had advocated the therapeutic use of calcium, vitamin D and ascorbic acid, and, in postmenopausal women, administration of estrogens; but with fractures or immobilization, intake of calcium-containing foods, such as milk, must be restricted to avoid dangerous piling up of calcium and kidney stones, and fluids must be forced. In recent years anabolic steroid hormones, principally oral androgens and estrogens, have been employed by Gordan and others to promote bone repair, lessen bone pain and decrease urinary excretion of calcium. While these hormones probably do not arrest the disease, they seem to stabilize it and bring relief of symptoms. More recently, Albright and Henneman demonstrated that very large doses of corticotropin (ACTH) or cortisone resulted in immediate cessation of bone pain, decrease in urinary excretion of calcium and histologic evidence of regression of the disease process. The large doses required, however, also produce dangerous side effects, such as psychosis and osteoporosis, indicating that such treatment probably should not be continued over long periods.
- Published
- 1959
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.